[Treatment of patent ductus arteriosus in premature infants by indomethacin].
Over a 4-year period, 63 premature babies presenting with patent ductus arteriosus were treated with indomethacin at two different dosage levels (0.1 and 0.2 mg/kg). For all infants the permanent closure rate was 68% (56% with 0.1 mg/kg and 75% with 0.2 mg/kg - n.s.) and the positive response rate (i.e. permanent and transient closure) 84%. There was no difference between the two dosages in the incidence of side-effects, particularly on diuresis, and in mortality and morbidity rates; the overall mortality rate was 31%. Pharmacokinetic studies performed in 51 cases did not show any difference related to indomethacin dosage. The changes observed after 2 or 3 doses resulted from improvement in haemodynamics. This study confirms the effectiveness of indomethacin in the treatment of patent ductus arteriosus and suggests an advantage for the 0.2 mg/kg dose.
D004231:Diuresis / Q000187:drug effects; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007213:Indomethacin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases; D007700:Kinetics
D007213:Indomethacin
Traitement du canal artériel du prématuré par l'indométacine.